Oramed Pharmaceuticals Inc. ORMP

4.73 (0.06) (1.25%) as of 25 Sep
Market cap
$199.3M
P/E
1.1×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Gross Profit
— — — —

+8 more quarters

R&D Expenses
— 1.59 1.99 1.15
SG&A Expenses
2.77 2.07 3.68 1.27
Operating Income
(2.77) (3.66) (5.67) (2.43)
Non-operating Income/Expense
104.35 53.10 15.47 61.88
EBT
101.59 49.44 9.80 59.45
Income Tax Provision
23.43 11.13 (0.21) 11.06
Income after Tax
78.16 38.31 10.01 48.39
Non-Controlling Interest
— — — (0.01)
Net Income Common
78.16 38.31 9.20 48.40
EPS (Basic)
1.90 0.94 0.23 1.16
EPS (Diluted)
1.84 0.91 0.24 1.13
Shares (Basic, Weighted)
41.04 40.77 41.40 41.76
Shares (Diluted, Weighted)
42.50 41.97 42.42 42.78
EBIT Margin
0.00% 0.00% 0.00% 0.00%
EBT margin
0.00% 0.00% 0.00% 0.00%
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
EBITDA
(2.73) (3.63) (5.64) (2.40)
EBIT
(2.77) (3.66) (5.67) (2.43)
Income from Continuous Operations
78.16 38.31 10.01 48.39
Consolidated Net Income/Loss
78.16 38.31 10.01 48.39
EPS (Basic, from Continuous Ops)
1.90 0.94 0.26 1.16
EPS (Diluted, from Cont. Ops)
1.84 0.91 0.25 1.13
EPS (Basic, Consolidated)
1.90 0.94 0.26 1.16
EPS (Diluted, Consolidated)
1.84 0.91 0.25 1.13
Shares (Diluted, Average)
42.50 41.97 41.30 42.78
EBITDA Margin
0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates